August 7, 2024 Experience Bansk Group $1.5 billion going-private acquisition of PetIQ We are advising Bansk Group on the transaction
August 7, 2024 Experience Revolution Medicines $500 million at-the-market offering The shares are listed on the Nasdaq Global Select Market
August 6, 2024 Experience AC Immune $80 million at-the-market offering We advised AC Immune on the offering
July 19, 2024 Experience Clariane €92 million reserved capital increase and €237 million rights offering We advised Clariane on its refinancing transactions
July 11, 2024 Experience IDEAYA Biosciences $302.5 million equity offering The common stock is listed on the Nasdaq Global Select Market
July 2, 2024 Experience Recursion Pharmaceuticals $230 million follow-on offering The shares are listed on the Nasdaq Global Select Market
July 2, 2024 Experience InflaRx $75 million at-the-market offering The shares are listed on the Nasdaq Global Market
June 18, 2024 Experience Tempus AI $410 million IPO The stock is listed on the Nasdaq Global Select Market
June 13, 2024 Experience ProKidney $140 million follow-on offerings We advised ProKidney on the offering
June 11, 2024 Experience Royalty Pharma $1.5 billion senior notes offering We advised Royalty Pharma on its investment-grade notes offering